Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | TP53 | P04637 | 2/20 | 0.71 |
| ▸ | PKM | P14618 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 4/20 | 0.60 |
| ▸ | ACHE | P22303 | 1/20 | 0.60 |
| ▸ | MIF | P14174 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.52 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.52 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4819273 | 0.83 | TP53 (1.00) | MAPTTP53PKMLMNAPOLB | |
| SCHEMBL4820187 | 0.83 | MAOB (0.76) | MAPTTP53PKMLMNAPOLB | |
| SCHEMBL4817800 | 0.83 | TP53 (0.76) | MAPTTP53PKMLMNAPOLB | |
| SCHEMBL4820635 | 0.83 | TP53 (0.76) | MAPTTP53PKMPOLBMAOB | |
| SCHEMBL4821180 | 0.82 | TP53 (0.79) | MAPTTP53PKMLMNAPOLB | |
| SCHEMBL4815694 | 0.81 | TP53 (0.74) | MAPTTP53PKMPOLBMAOB | |
| SCHEMBL4820220 | 0.79 | TP53 (0.69) | MAPTTP53PKMPOLBMAOB | |
| SCHEMBL4813586 | 0.79 | MAPT (0.79) | MAPTTP53PKMLMNAPOLB | |
| SCHEMBL4822418 | 0.77 | TP53 (0.74) | MAPTTP53PKMPOLBMAOB | |
| SCHEMBL4818996 | 0.77 | MAOB (0.74) | MAPTTP53PKMPOLBMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7411076-B2 | such as 2-chloro-N-(7-hydroxy-2-oxo-2H-1-benzopyran-3-yl)benzamide, used for intensifying the effects of cancer therapy based on DNA injury; protein kinase inhibitors; side effect reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-08-12 | — | — | US | disclosed |
| US-20050054717-A1 | Coumarin derivative | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054717-A1 | Coumarin derivative | ERCC2, ERCC4, DDB1 | MAPT 4772/4885TP53 81/4885PKM 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.